Dopamine transporter SPECT imaging in parkinson disease and dementia

PET Clinics

Volumn 8, Issue 4, 2013, Pages 459-467

  Surasi, Devaki Shilpa ^a   Peller, Patrick J ^b   Szabo, Zsolt ^c   Mercier, Gustavo ^d   Subramaniam, Rathan ^c  

^a University of Alabama at Birmingham   (United States)

^b MAYO CLINIC   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dementia; Dopamine; Parkinson disease; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; LEVODOPA; NORTROPANE DERIVATIVE; PLACEBO; PRAMIPEXOLE;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG EFFECT; ESSENTIAL TREMOR; HUMAN; IATROGENIC DISEASE; IMAGE QUALITY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84885119235     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2013.08.006     Document Type: Review

References (46)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56(1):33-9. (Pubitemid 29046907)
2. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14(2):317-35.
3. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatr 1994;57(6):672-81.
4. Hague SM, Klaffke S, Bandmann O. Neurodegenerative disorders: Parkinson's disease and Huntington?s disease. J Neurol Neurosurg Psychiatr 2005; 76(8):1058-63. (Pubitemid 41081275)
5. Neumeyer JL, Wang S, Gao Y, et al. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. JMedChem1994;37(11):1558-61. (Pubitemid 24195468)
6. Marvin M, Goldenberg PT. Pharmaceutical Approval Update 2011;36(3):162-4. PMCID: PMC3086106.
7. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995; 15(3 Pt 1):1714-23.
8. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318(14):876-80. (Pubitemid 18090271)
9. Varrone A, Sansone V, Pellecchia MT, et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. Eur J Nucl Med Mol Imaging 2008;35(7):1343-9.
10. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version. Eur J Nucl Med Mol Imaging 2010;37(2):443-50.
11. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35(2):424-38.
12. Morton RJ, Guy MJ, Clauss R, et al. Comparison of different methods of DatSCAN quantification. Nucl Med Commun 2005;26(12):1139-46. (Pubitemid 41677606)
13. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.
14. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46(1):231-7.
15. Vlaar AM, van Kroonenburgh MJ, Kessels AG, et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27.
16. Asenbaum S, Pirker W, Angelberger P, et al. [123I] beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105(10-12): 1213-28. (Pubitemid 29017402)
17. Haapaniemi TH, Ahonen A, Torniainen P, et al. [123I] beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001; 16(1):124-30. (Pubitemid 36041126)
18. Huang WS, Lin SZ, Lin JC, et al. Evaluation of earlystage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med 2001;42(9):1303-8.
19. Muller T, Farahati J, Kuhn W, et al. [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol 1998;39(1): 44-8. (Pubitemid 28024931)
20. Schwarz J, Linke R, Kerner M, et al. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 2000; 57(2):205-8. (Pubitemid 30097187)
21. Van Laere K, De Ceuninck L, Dom R, et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004;31(8):1119-27. (Pubitemid 39050179)
22. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43.
23. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508.
24. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119(Pt 2):585-91.
25. PirkerW, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal beta-CIT SPECTstudy. MovDisord 2002;17(1):45-53. (Pubitemid 36041259)
26. Chouker M, Tatsch K, Linke R, et al. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001;22(6):721-5. (Pubitemid 32525942)
27. Staffen W, Mair A, Unterrainer J, et al. Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT. J Neural Transm 2000; 107(5):543-52. (Pubitemid 30251738)
28. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I] beta-CIT. Mov Disord 1999;14(3):436-42. (Pubitemid 30011653)
29. The Parkinson's Progression Markers Initiative (PPMI). 2010. Prog Neurobiol 2011;95(4):629-35. http://dx.doi.org/10.1016/j.pneurobio.2011.09.005. Epub 2011 Sep 14.
30. Jann MW. Advanced strategies for treatment of Parkinson's disease: the role of early treatment. Am J Manag Care 2011;17(Suppl 12):S315-21.
31. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287(13):1653-61.
32. Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):IV37-42.
33. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012;8(1):15-21.
34. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatr 1988;51(6):850-4.
35. Lorberboym M, Treves TA, Melamed E, et al. [123I]-FP/CIT SPECT imaging for distinguishing druginduced parkinsonism from Parkinson's disease. Mov Disord 2006;21(4):510-4.
36. Booij J, Speelman JD, Horstink MW, et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28(3):266-72.
37. Gerasimou G, Costa DC, Papanastasiou E, et al. SPECT study with I-123-ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease? Ann Nucl Med 2012; 26(4):337-44.
38. Elble RJ, Tremor Research Group. Report from a U.S. conference on essential tremor. Mov Disord 2006;21(12):2052-61. (Pubitemid 46140411)
39. Jenkins IH, Bain PG, Colebatch JG, et al. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol 1993;34(1):82-90. (Pubitemid 23188731)
40. Isaias IU, Canesi M, Benti R, et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun 2008;29(4):349-53. (Pubitemid 351644383)
41. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15(3):503-10. (Pubitemid 30333223)
42. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3(1):19-28. (Pubitemid 38018924)
43. Lopez OL, Becker JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002;59(1):43-6. (Pubitemid 34052554)
44. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122(Pt 8):1449-68. (Pubitemid 29374123)
45. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatr 2007;78(11):1176-81. (Pubitemid 350057277)
46. McKeith I, O?Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study. Lancet Neurol 2007; 6(4):305-13. (Pubitemid 46367938)